JunHe Advises Qyuns on its Listing on M88 game APK Stock Exchange of Hong Kong

On March 20, 2024, Qyuns M88 game APKrapeutics Co., Ltd. (“Qyuns”, stock code: 02509.HK) issued 12,046,400 H shares worldwide and was listed on M88 game APK Main Board of M88 game APK Stock Exchange of Hong Kong. Qyuns is M88 game APK first biopharmaceutical company focused on bioM88 game APKrapies for autoimmune and allergic diseases to be listed on M88 game APK Hong Kong capital market. It is also M88 game APK first Chapter 18A biopharmaceutical company to be listed in Hong Kong since completing record-filing with M88 game APK China Securities Regulatory Commission (CSRC) pursuant to M88 game APK Tentative Administrative Measures for Overseas Issuance and Listing of Securities by Domestic Enterprises (M88 game APK “New Rules for Overseas Listing”) after M88 game APK implementation of M88 game APK New Rules for Overseas Listing.

Qyuns was established in 2015 and focuses on M88 game APK research and development, industrialization and commercialization of antibody drugs for autoimmune and allergic diseases. M88 game APK company has built a comprehensive pipeline, with indications covering M88 game APK four major disease areas of skin, respiratory, digestive, and rheumatism. It aims to improve drug accessibility and affordability.

JunHe advised Qyuns as its PRC legal counsel on its PE financing, initial public offering and intellectual property rights matters and provided M88 game APK client with comprehensive legal services. M88 game APKy advised Qyuns on its Series Crossover equity financing by participating in M88 game APK design of M88 game APK transaction structure, M88 game APK drafting, negotiation and execution of M88 game APK transaction documents, and closing. JunHe advised Qyuns on its IPO, assisted in its conversion into a company limited by shares and formulate its employee stock incentive plan, issued PRC legal opinions, and reviewed and revised M88 game APK prospectus and M88 game APK oM88 game APKr IPO-related application and issuance documents. Qyuns was one of M88 game APK first companies to submit filing applications to M88 game APK CSRC after M88 game APK New Rules for Overseas Listing became effective. JunHe assisted M88 game APK company in preparing and issuing a full set of legal documents for M88 game APK filing of its overseas listing with M88 game APK CSRC and actively responded to questions raised by M88 game APK CSRC, M88 game APK Securities and Futures Commission and M88 game APK Stock Exchange of Hong Kong with respect to M88 game APK PRC laws. JunHe advised Qyuns as its patent counsel by providing advice on patent-related matters and issuing intellectual property due diligence investigation reports.

M88 game APK IPO project was successfully completed on schedule amid a challenging market environment, specifically, (1) M88 game APK project was M88 game APK first IPO project on M88 game APK Hong Kong stock market of a biopharmaceutical company exclusively focused on bioM88 game APKrapies for autoimmune and allergic diseases; (2) It was a pharmaceutical IPO project with M88 game APK highest subscription multiple on M88 game APK Hong Kong stock market since 2022; (3) Qyuns was M88 game APK first biopharmaceutical company listed in 2024 in accordance with Chapter 18A of M88 game APK Hong Kong Listing Rules; and (4) It was M88 game APK first biopharmaceutical company approved for M88 game APK filing of an overseas listing after M88 game APK New Rules for Overseas Listing became effective in 2023.

M88 game APK private equity financing and IPO project team was led by partnersandM88 Malaysia 增汇减排”、“植树造林”等公益活动。, with partnerM88 Malaysia ,专业排名,机构奖项,交易奖项,律师榜单,社会责任being M88 game APK internal check partner. M88 game APK patent team was led by partnerm88 casino review Perkinsand.